id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12854 R48476 |
Thomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.71 [0.09;5.89] C excluded (control group) |
7/490 1/50 | 8 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12855 R48486 |
Thomas (Carbamazepine) (Controls unexposed, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.53 [0.20;1.45] C | 7/490 9/340 | 16 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S382 R16393 |
Tomson (Carbamazepine), 2018 | Cardiac malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.42 [1.29;4.54] C | 28/1,957 15/2,514 | 43 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6290 R16963 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Cardiac defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.98 [0.85;4.58] C | 14/1,657 9/2,098 | 23 | 1,657 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10289 R37670 |
Vajda (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.87 [0.17;4.35] C excluded (control group) |
3/361 3/315 | 6 | 361 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9830 R37665 |
Vajda (Carbamazepine) (Controls unexposed, sick), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.22 [0.13;11.86] C | 3/361 1/147 | 4 | 361 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5937 R23780 |
Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 | Cardiovascular anomalies | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 1.51 [0.30;7.51] C | 3/1,033 3/1,562 | 6 | 1,033 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5483 R15645 |
Bànhidy (Carbamazepine), 2011 | Cardiovascular congenital abnormalities | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 0.80 [0.16;3.88] C | 4/14 5/15 | 9 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9845 R35321 |
Mawer (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Cardiac Malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.56 [0.01;28.68] C excluded (control group) |
0/66 0/37 | 0 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9846 R35327 |
Mawer (Carbamazepine) (Controls unexposed, disease free), 2010 | Cardiac Malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.44 [0.06;35.82] C excluded (control group) |
0/66 1/285 | 1 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9847 R35333 |
Mawer (Carbamazepine) (Controls unexposed, sick), 2010 | Cardiac Malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.62 [0.01;31.78] C | 0/66 0/41 | 0 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S302 R15853 |
Artama (Carbamazepine), 2005 | Cardiovascular | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 0.50 [0.13;1.93] C | 3/805 7/939 | 10 | 805 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6509 R17928 |
Canger (Carbamazepine), 1999 | Cardiac malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.22 [0.00;11.25] C | 0/113 0/25 | 0 | 113 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6685 R18583 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Heart disease | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
24.60 [0.40;1512.72] C excluded (control group) |
0/3 0/62 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6689 R18700 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Heart disease | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.87 [0.03;29.20] C | 0/3 1/8 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6823 R19299 |
Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 | Cardiac anomaly | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
5.40 [0.31;93.62] C excluded (control group) |
1/11 1/55 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6825 R19349 |
Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 | Cardiac anomaly | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 6.79 [0.25;182.34] C | 1/11 0/22 | 1 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 11 studies | 1.29 [0.81;2.05] | 113 | 6,510 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine) (Controls exposed to Lamotrigine, sick; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine) (Controls exposed to Lamotrigine, sick; 6: Carbamazepine; 7: Carbamazepine) (Controls unexposed, sick; 8: Carbamazepine; 9: Carbamazepine; 10: Carbamazepine) (Controls unexposed, sick; 11: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.2368 (by Egger's regression)
slope=0.7625 (0.3899); intercept=-0.7601 (0.5997); t=1.2676; p=0.2368
excluded 6685, 6823, 9845, 9846, 10289, 12854